This page is available in multiple languages
Select Language

Gentian Diagnostics lists on Oslo Børs

Back

Oslo – 25 June 2021 – Euronext today congratulates Gentian Diagnostics on its transfer from Euronext Growth to Oslo Børs (ticker code: GENT).

Gentian serves the global market for diagnostic tests with sensitive biochemical products developed by leveraging proprietary, disruptive, diagnostic technologies. The company was listed on Euronext Growth in December 2016.

Hilja Ibert, CEO of Gentian Diagnostics, said: "We made a promise to our shareholders when we were listed on Euronext Growth that we would aim for the main list when the company had matured. I’m pleased that we have now reached this milestone, and that we have access to a high-quality investor base as we work towards our ambitious targets of long-term growth and value creation. Through our diversified portfolio of tests, we provide a solid foundation for growth and value creation. To deliver on our ambition, we aim to bring one additional product to market per year and expand market access through achieving additional regulatory approvals and commercial partners."

About Gentian Diagnostics

Gentian is a Norway based, international company working on global solutions that change health care. With in-house production, R&D and marketing, Gentian serves the global market for diagnostic tests with sensitive biochemical products developed by leveraging proprietary, disruptive, diagnostic technologies. Current and pipeline products contribute to improved diagnostics and cost reductions in treatment of kidneys, inflammation, cardiovascular diseases, cancer and viral infections.

Press Release Footer

About Euronext 
Euronext is the leading European capital market infrastructure, covering the entire capital markets value chain, from listing, trading, clearing, settlement and custody, to solutions for issuers and investors. Euronext runs MTS, one of Europe’s leading electronic fixed income trading markets, and Nord Pool, the European power market. Euronext also provides clearing and settlement services through Euronext Clearing and its Euronext Securities CSDs in Denmark, Italy, Norway, and Portugal. As of December 2024, Euronext’s regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway, and Portugal host over 1,800 listed issuers with around €6 trillion in market capitalisation, a strong blue-chip franchise and the largest global centre for debt and fund listings. With a diverse domestic and international client base, Euronext handles 25% of European lit equity trading. Its products include equities, FX, ETFs, bonds, derivatives, commodities and indices. 
For the latest news, follow us on X (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2025, Euronext N.V. - All rights reserved.